Insulet price target lowered to $208 from $343 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Insulet to $208 from $343 and keeps an Equal Weight rating on the shares after updating its model following Q2 results. Though the firm recognizes “it’s still early in the debate,” it has lowered out-year estimates in light of recent GLP-1 data releases that limit visibility into the business’s long-term growth trajectory.